ESTERN Medical is a full-service CRO bridging the USA and Latin America, with regional presence in Mexico, Colombia, Chile, Argentina and Brazil, running Phase I–IV programs across pharma and devices. It's a solid pick if you want a US–LATAM full-service partner across the trial lifecycle. bioaccess® is a US–LATAM CRO too, but exclusively for first-in-human. The bioaccess® differentiators are FIH-only focus, a 12-month protocol-to-LPLV written guarantee, a 10-country Latin American footprint with 50+ pre-qualified sites, and a track record of 3 Fortune 500 acquisitions of client companies.
| Metric | bioaccess® | ESTERN Medical |
|---|---|---|
| Focus | FIH-only for MedTech, Biopharma & Radiopharma startups — the entire business | Category-level: full-service or FIH-adjacent CRO; first-in-human is one line of business among others |
| Country footprint | U.S. + 10 Latin American countries, 50+ pre-qualified sites | Category-level: narrower geographic optionality (single country or a shorter LATAM list) |
| U.S. regulatory anchoring | In-house U.S. regulatory strategy: FDA Pre-Sub / Q-Sub, IDE, 510(k), De Novo, PMA, HDE, IND — designed as the anchor for LATAM execution | Category-level: varies by shop; U.S. FDA strategy is not always the anchoring lens |
| Timeline commitment | 12-month protocol-to-LPLV written guarantee — we work at our cost if we miss agreed milestones | Category-level: written milestone guarantees are uncommon in the CRO market |
| FIH start (protocol → first patient) | 6–8 weeks via FIH FastTrack | Category-level: varies; not typically compressed to a 6–8 week start |
| Typical per-patient cost | $15K–$35K | $40K–$75K in US/EU benchmark ranges; LATAM shops typically fall between the two |
| Track record on FIH exits | 3 Fortune 500 acquisitions of bioaccess® clients (Mitralign → Edwards; ClarVista → Alcon; ForSight VISION5 → Allergan/AbbVie) | Category-level: acquisition track records vary; this specific FIH-to-Fortune-500 pattern is bioaccess®'s. |
| Team credentials | ACRP-certified project managers and monitors; founded 2010 by two interventional cardiologists (one Harvard-trained) | Category-level: reputable teams; specific credential mix varies |
| Regulatory standard for devices | ISO 14155 + Declaration of Helsinki; data eligible for FDA submission/review under 21 CFR 812.28 | ISO 14155-aligned; category-standard for medical-device trials |
| Post-trial support | Latin American market access, device registration in 10 countries, HTA & payer engagement | Category-level: post-trial support scope varies by shop |
Comparison uses widely-known category facts about ESTERN Medical and published US/EU benchmark ranges — not ESTERN Medical-specific figures. bioaccess® figures reflect our FIH FastTrack operating model.
ESTERN Medical and bioaccess® overlap on geography — both are US–LATAM CROs — but not on scope. ESTERN is full-service across Phase I–IV and both pharma and devices; bioaccess® is exclusively first-in-human for MedTech, Biopharma and Radiopharma startups. Different jobs, different operating models.
The bioaccess® FIH-only model is what supports the 12-month protocol-to-LPLV written guarantee, the 6–8 week study start, and the 4–8 week ethics approval. It's also what supports a track record of 3 Fortune 500 acquisitions of client companies (Mitralign → Edwards Lifesciences; ClarVista Medical → Alcon; ForSight VISION5 → Allergan/AbbVie) — a specific FIH-to-strategic-exit pattern.
Data is generated under ISO 14155 and the Declaration of Helsinki and is eligible for FDA submission and review under 21 CFR 812.28 (for devices) or ICH E6 for drugs and biologics — a case-by-case regulatory determination, not a guarantee of clearance or approval. If your program is broader than FIH, ESTERN Medical is a capable choice; if FIH is the job, bioaccess® is purpose-built for it.
Only in a narrow slice. ESTERN Medical is a capable, reputable CRO. bioaccess® is purpose-built for a single job: first-in-human clinical trials for MedTech, Biopharma and Radiopharma startups, executed across the U.S. and Latin America. If your program is a global pivotal or a post-market study, ESTERN Medical is often a better fit. If your program is your first-in-human trial and you need clean, FDA-bridgeable data on a startup budget and timeline, bioaccess® is purpose-built for it.
Clinical data from studies conducted outside the U.S. under ISO 14155 and the Declaration of Helsinki is eligible for FDA submission and review under 21 CFR 812.28 (for devices) and comparable ICH E6 pathways for drugs and biologics. Acceptance is a case-by-case regulatory determination, not a guarantee of clearance or approval — our regulatory team designs the study with the target FDA submission (IDE, 510(k), De Novo, PMA, HDE, IND) as the anchor.
A standard 10-patient, single-site FIH study through FIH FastTrack runs roughly $350K all-in, with a 12-month protocol-to-LPLV written guarantee and a 6–8 week study start. Per-patient cost is $15K–$35K vs. $40K–$75K in US/EU benchmark ranges. Ethics approval is 4–8 weeks in Latin American jurisdictions vs. 6–12 months in the US/EU.
Yes — sponsors regularly do. A common pattern is to run FIH with bioaccess® in Latin America to generate clean, regulator-ready data fast, then hand off to ESTERN Medical (or another CRO suited to that later-phase work) for a multi-region pivotal, registration, or post-market program. Our regulatory strategy is designed to be portable so that data and documentation transfer cleanly to any downstream CRO.
Geography overlaps; scope does not. ESTERN Medical is full-service across Phase I–IV and pharma + devices. bioaccess® is FIH-only for MedTech, Biopharma, and Radiopharma startups. Because of that exclusivity we can commit to a 12-month protocol-to-LPLV written guarantee, a 6–8 week study start, and $15K–$35K per patient — with the specific track record of 3 Fortune 500 acquisitions of client companies. If your program is broader than FIH, ESTERN Medical is a strong US–LATAM option.
You need one vendor for the full trial lifecycle across Phase I–IV inside Latin America, or a pharma program that isn't a first-in-human study. In that case, a full-service US–LATAM shop like ESTERN Medical is a natural fit. bioaccess® is the better fit when the specific next milestone is a clean, FDA-bridgeable first-in-human dataset on a fundable timeline.
All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call